Abstract:B271 Introduction: The tumor suppressor p53 is a key regulator of cell cycle, apoptosis, senescence and DNA repair. Due to its important role in oncogenesis, it is not surprising that p53 function is compromised in all human cancers. In half the cancers, p53 gene is directly mutated/deleted, rendering p53 protein inactive, while in the remaining cancers with wild-type p53, p53 function is effectively inhibited by its cellular endogenous inhibitor the minute double minute 2 (MDM2) protein through direct interaction. Thus, targeting the MDM2-p53 interaction by small-molecule inhibitors is a promising approach for the reactivation of p53 function, and is being intensely pursued as a cancer therapeutic strategy. Since MDM2 is an essential regulator of p53 activity, there is a serious concern that unleashing p53 function by small-molecule inhibitors of MDM2 may result in toxicity to normal healthy tissues, casting doubts on the suitability of MDM2 inhibitors as potential cancer therapeutic strategy. Methods: We employed multiple human cancer cell line and xenograft tumor models, including SJSA-1 osteosarcoma and LNCaP prostate cancer, and performed following assays/procedures: 1) Binding affinity was determined in fluorescence polarization-based binding assays, 2) cell growth by WST assay, 3) cell cycle by BrdU incorporation, 4) apoptosis by Annexin V staining, 5) MDM2-p53 interaction by co-immunoprecipitation, 6) p53 was downregulated by siRNA oligonucleotide, 7) oral availability by pharmacokinetic (PK) studies, 8) p53 activation by immunohistochemistry and immunoblotting, 9) cell proliferation in tissues by BrdU incorporation, 10) apoptosis in tissues by TUNEL staining, 11) anti-tumor activity in xenograft models, 12) toxicity by animal body weight and necropsy, and 13) normal tissue damage by histopathology. Results: Employing a computational structure-based approach, we have designed a new, highly potent (K i = 5 nM) and selective (>10,000-fold over MDM2 homologue MDMX), orally-available small-molecule MDM2 inhibitor (MI-219) with a distinctively different chemical structure from other known MDM2 inhibitors. MI-219 disrupts intracellular MDM2-p53 interaction in cancer cell lines, leading to accumulation and activation of p53. p53 pathway is activated in both normal and cancer cells with wild-type p53, and leads to cell cycle arrest in both normal and cancer cells with wild-type p53, but selective apoptosis in cancer cells. Induction of cell cycle arrest and apoptosis is strictly p53-dependent. MI-219 has excellent oral bioavailability in mice and rats. A single oral dose of MI-219 induces rapid, but transient, activation of p53 in xenograft tumors and normal mouse tissues, strongly correlating with the plasma levels of MI-219. Multiple oral dosing of MI-219 potently inhibits tumor growth without causing animal weight loss or other signs of toxicity. Importantly, therapeutically effective dose schedules of MI-219 do not result in any damage to normal radio-sensitive and radio-resistant tissues. Conclusion: We conclude that activation of p53 by potent and specific small-molecule MDM2 inhibitors is selectively toxic to tumors without causing damage to normal tissues. Our study thus provides a strong rationale to advance MI-219 or its analogues for clinical development as a new and promising cancer therapeutic strategy.

A Novel Naphthalimide Compound Restores P53 Function In Non-Small Cell Lung Cancer By Reorganizing The Bak Center Dot Bcl-Xl Complex And Triggering Transcriptional Regulation

Inhibition of nonsense-mediated decay rescues p53/ isoform expression and activates the p53 pathway in and select-mutant cancers

Inhibition of Nonsense-Mediated Decay Rescues P53β/γ Isoform Expression and Activates the P53 Pathway in MDM2-overexpressing and Select P53-Mutant Cancers

Pharmacological Activation of the P53 Pathway by a New Compound CYZ2017 Exerts Anti-Tumor Effects

Small-Molecule Modulators Of P53 Family Signaling And Antitumor Effects In P53-Deficient Human Colon Tumor Xenografts

Design and synthesis of anticancer 1-hydroxynaphthalene-2-carboxanilides with a p53 independent mechanism of action

B1, a novel naphthalimide-based DNA intercalator, induces cell cycle arrest and apoptosis in HeLa cells via p53 activation

A naturally derived small molecule compound suppresses tumor growth and metastasis in mice by relieving p53-dependent repression of CDK2/Rb signaling and the Snail-driven EMT

Novel 9-Methylanthracene Derivatives as p53 Activators for the Treatment of Glioblastoma Multiforme

A novel triazolonaphthalimide induces apoptosis and inhibits tumor growth by targeting DNA and DNA-associated processes.

Design, synthesis and bioactivity of novel naphthalimide-benzotriazole conjugates against A549 cells via targeting BCL2 G-quadruplex and inducing autophagy

A Novel Orally Active Mdm2 Inhibitor (Mi-219) Activates the P53 Pathway and is Selectively Toxic to Tumor Cells

Designed novel nuclear localizing anticancer peptide targets p53 negative regulator MDM2 protein

The pharmalogical reactivation of p53 function improves breast tumor cell lysis by granzyme B and NK cells through induction of autophagy

Novel structured ADAM17 small-molecule inhibitor represses ADAM17/Notch pathway activation and the NSCLC cells' resistance to anti-tumour drugs

A subset of CB002 xanthine analogs bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53

Synthesis, characterization, and anti-cancer potential of novel p53-mediated Mdm2 and Pirh2 modulators: an integrated In silico and In vitro approach

Design, synthesis and anticancer activity of β-carboline based pseudo-natural products by inhibiting AKT/mTOR signaling pathway

A Novel Aniline Derivative from Peganum Harmala L. Promoted Apoptosis Via Activating PI3K/AKT/mTOR-Mediated Autophagy in Non-Small Cell Lung Cancer Cells.

Upregulation of wild-type p53 by small molecule-induced elevation of NQO1 in non-small cell lung cancer cells

Selective Targeting P53wt Lung Cancer Cells Harboring Homozygous P53 Arg72 by an Inhibitor of CypA.